Activity of DSA against anaerobically adapted Mycobacterium bovis BCG in vitro

Nicole M. Parrish, Chiew G. Ko, James D. Dick

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


DSA is a β-sulfonylacetamide with in vitro activity against pathogenic mycobacteria. Although the enzymatic target(s) of DSA has not been identified, studies to date suggest that this class of compounds may interfere directly or indirectly with ATP synthase and other components of the mycobacterial respiratory chain. In this study we further evaluated the in vitro activity of DSA against anaerobically adapted BCG using two established models. DSA killed BCG in the anaerobic Wayne model. Bactericidal activity ranged from >99% to 60%. DSA killed rifampin-tolerant persisters with a reduction in viable counts of 1.5 log10 versus controls. Conclusive identification of the DSA-specific target(s) will permit a better understanding of the unique mechanism of action of this class of compounds against both aerobically growing and anaerobically adapted bacilli in vitro.

Original languageEnglish (US)
Pages (from-to)325-327
Number of pages3
Issue number4
StatePublished - Jul 2009


  • Latency
  • Mycobacterium tuberculosis
  • Rifampin-tolerant persisters
  • Wayne model
  • n-decanesulfonylacetamide

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Activity of DSA against anaerobically adapted Mycobacterium bovis BCG in vitro'. Together they form a unique fingerprint.

Cite this